With increasing rates of cannabis and hallucinogen use, the Michigan Society of Anesthesiologists (MSA) is urging patients to disclose any such substance use to their physicians before undergoing surgery. This initiative aims to enhance patient safety and ensure effective anesthesia during surgical procedures.
According to a study by the University of Michigan, the usage of cannabis and hallucinogens among adults is at an all-time high. Dr. Matt Dellaquila, president-elect of the MSA, explained that these substances can complicate the anesthetic process, stating, ‘All of these substances can have a real impact on the delivery of your anesthetic.’ He further emphasized the need for thorough patient history before surgery to mitigate risks.
The release from MSA noted that smoking in any form, including cannabis, can impair lung function, further complicating anesthesia decisions. ‘Patients may not realize that these naturally derived substances affect anesthesia,’ said MSA President Dr. Michael Lewis. He pointed out that marijuana consumption prior to surgery can heighten the risk of cardiovascular incidents.
Although marijuana remains illegal at the federal level, Michigan legalized recreational use in 2018. Additionally, many hallucinogens are classified as Schedule I drugs, yet incidents of overdose from these substances are rare, according to the U.S. Drug Enforcement Administration. Certain regions of Michigan have decriminalized the use of psychedelics, and research into their therapeutic applications is expanding, particularly at the University of Michigan Psychedelic Center.
The prevalence of substance use disclosure is critical, as more patients admit to using cannabis and hallucinogens. Dr. Dellaquila noted, ‘Since it’s becoming more common, we think it’s important that the patients let us know about it if they’re on it.’
Julie Barron, president of the Michigan Psychedelic Society, echoed the necessity of these discussions, stating, ‘We really need to have these conversations.’ However, she acknowledged the hesitation some patients have regarding potential legal implications of disclosing substance use. Studies indicate that many psychedelic users do not discuss their usage with healthcare providers due to stigma, lack of provider education, and concerns over legal repercussions.
Dr. Dellaquila reassured that substance use disclosures are protected under the Health Insurance Portability and Accountability Act (HIPAA), ensuring confidentiality. He advocated for creating a judgment-free environment for patients, where they feel safe to share their substance use history. Acknowledging the societal stigma surrounding this issue, he urged, ‘We want people to talk honestly about what’s going on in their medical history.’
In collaboration with the Michigan Psychedelic Society, MSA is actively promoting workshops to assist healthcare providers in effectively discussing psychedelic use with patients. Barron emphasized the importance of developing clear guidelines and educational resources for health professionals to facilitate these conversations.
Decriminalizing psychedelic use for medical treatments could significantly reduce the stigma surrounding substance disclosure, Barron asserted. ‘Can we actually allow the opportunity for people who might not want to do it on their own, or might not want to do it in a community or spiritual or religious situation, to do it in a therapeutic environment?’ she posited, reiterating the need for parallel efforts in legislative reforms and medical legalization.
Comments are closed